{"id":"https://openalex.org/W3208553056","doi":"https://doi.org/10.1182/blood-2021-144914","title":"First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios","display_name":"First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3208553056","doi":"https://doi.org/10.1182/blood-2021-144914","mag":"3208553056"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-144914","doi":"https://doi.org/10.1182/blood-2021-144914","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-144914","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003015868","display_name":"Rafa\u00ebl Fonseca","orcid":"https://orcid.org/0000-0002-5938-3769","observed_orcids":["https://orcid.org/0000-0002-5938-3769"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rafael Fonseca","raw_affiliation_strings":["Mayo Clinic Arizona, Phoenix, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Arizona, Phoenix, AZ","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024315315","display_name":"Thierry T.F. Facon","orcid":"https://orcid.org/0000-0001-7705-8460","observed_orcids":["https://orcid.org/0000-0001-7705-8460"]},"institutions":[{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Thierry Facon","raw_affiliation_strings":["Lille University Hospital, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lille University Hospital, Lille, France","institution_ids":["https://openalex.org/I3018718406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001334485","display_name":"Mahmoud Hashim","orcid":"https://orcid.org/0000-0002-5775-9590","observed_orcids":["https://orcid.org/0000-0002-5775-9590"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Mahmoud Hashim","raw_affiliation_strings":["Janssen Pharmaceutica NV, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutica NV, Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108462441","display_name":"Sandhya C. Nair","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Sandhya Nair","raw_affiliation_strings":["Janssen Pharmaceutica NV, Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutica NV, Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046342118","display_name":"Jianming He","orcid":"https://orcid.org/0000-0002-5015-3713","observed_orcids":["https://orcid.org/0000-0002-5015-3713"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianming He","raw_affiliation_strings":["Janssen Global Services, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Global Services, Raritan, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087364145","display_name":"Eric M. Ammann","orcid":"https://orcid.org/0000-0001-5882-5388","observed_orcids":["https://orcid.org/0000-0001-5882-5388"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric M. Ammann","raw_affiliation_strings":["Janssen Global Services, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Global Services, Raritan, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085549618","display_name":"Annette Lam","orcid":"https://orcid.org/0000-0003-2037-3464","observed_orcids":["https://orcid.org/0000-0003-2037-3464"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annette Lam","raw_affiliation_strings":["Janssen Global Services, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Global Services, Raritan, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082298947","display_name":"Mark A. Wildgust","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Wildgust","raw_affiliation_strings":["Janssen Global Services, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Global Services, Raritan, NJ","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026574827","display_name":"Shaji Kunnathu Kumar","orcid":"https://orcid.org/0000-0001-5392-9284","observed_orcids":["https://orcid.org/0000-0001-5392-9284"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shaji Kumar","raw_affiliation_strings":["Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"118","last_page":"118"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9620000123977661},{"id":"https://openalex.org/keywords/transplant-ineligible-patients","display_name":"transplant-ineligible patients","score":0.9629999995231628},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.8370000123977661},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9800000190734863},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.996999979019165},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.8899999856948853},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8180000185966492},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.9340000152587891},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8669999837875366},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9610000252723694},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6290000081062317},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.7689999938011169},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.5260000228881836}],"concepts":[{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.9812303781509399},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.8589597940444946},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6964359283447266},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6475518941879272},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.6063206791877747},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5843464732170105},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5517133474349976},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5004456043243408},{"id":"https://openalex.org/C3019258254","wikidata":"https://www.wikidata.org/wiki/Q1423317","display_name":"Second line","level":3,"score":0.43914878368377686},{"id":"https://openalex.org/C2993493390","wikidata":"https://www.wikidata.org/wiki/Q5453208","display_name":"First line","level":2,"score":0.2891738712787628}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-144914","doi":"https://doi.org/10.1182/blood-2021-144914","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-144914","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4366082830","https://openalex.org/W2901244884","https://openalex.org/W2118465399","https://openalex.org/W4229333964","https://openalex.org/W2510398184","https://openalex.org/W4233225695","https://openalex.org/W4387003806","https://openalex.org/W2605594161","https://openalex.org/W1996748901","https://openalex.org/W3121407702"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Despite":[2],"recent":[3,45],"treatment":[4],"(tx)":[5],"advances":[6],"that":[7,65,196,632,653,673],"have":[8,63,105,507],"improved":[9,526],"overall":[10],"survival":[11,119,289,519],"(OS),":[12],"multiple":[13],"myeloma":[14,787],"(MM)":[15],"remains":[16],"a":[17,149,203,269,281,442],"mostly":[18],"incurable":[19],"malignancy.":[20],"Txs":[21],"become":[22],"less":[23],"effective":[24],"with":[25,70,86,111,293,373,393,468,535,559,562,588,603,614,625,676,680,692,702],"each":[26],"successive":[27],"line":[28],"of":[29,90,151,176,208,261,324,362,549,688,712,722,744,759,777,786,884,898,929,943,969,985,998],"therapy":[30,568],"(LOT).":[31],"The":[32,296,406,547],"rapidly":[33],"evolving":[34],"tx":[35,43,57,97,181,205,215,244,278,304,383,459,605,627,726],"landscape":[36],"has":[37],"raised":[38],"questions":[39],"about":[40,56],"the":[41,115,125,157,174,227,258,369,403,410,456,464,483,575,580,634,693,710,714,720],"optimal":[42],"sequence;":[44],"trial":[46,184],"data":[47,62,185,491,664],"may":[48,434,682],"be":[49,109,187,358,435,455],"useful":[50],"to":[51,88,108,189,232,256,287,357,360,381,422,431,454,600,685,718],"develop":[52],"and":[53,131,141,163,235,245,318,340,375,433,470,505,515,517,554,619,823],"test":[54],"hypotheses":[55],"sequencing.":[58],"However,":[59],"real-world":[60],"(RW)":[61],"shown":[64],"while":[66],"most":[67],"patients":[68],"(pts)":[69],"newly":[71],"diagnosed":[72],"MM":[73],"(NDMM)":[74],"receive":[75],"first-line":[76],"(1L)":[77],"tx,":[78],"attrition":[79,228,407,572,617,666],"rates":[80,229,451,573,667],"are":[81,500],"high":[82],"in":[83,156,221,291,328,338,344,350,364,368,402,463,496,503,524,571,583,638,668,674,707,728,797,841,851,861,871],"later":[84,112,200,270,646],"LOT,":[85,113],"up":[87,684],"50%":[89],"transplant":[91],"ineligible":[92],"(TIE)":[93],"pts":[94,102,152,292,363,427,495,613,655,675,723],"receiving":[95],"no":[96,167],"beyond":[98],"1L.":[99],"As":[100],"many":[101,506,654],"will":[103],"not":[104,224,649,657],"an":[106,436,589,741,756,774,881,895,926,940,966,982,995],"opportunity":[107],"salvaged":[110],"achieving":[114,633],"longest":[116,635],"possible":[117,636],"progression-free":[118],"(PFS)":[120],"upfront":[121],"is":[122,202],"critical.":[123],"In":[124,148,173],"MAIA":[126,418,504],"trial,":[127],"daratumumab":[128],"(DARA),":[129],"lenalidomide,":[130,162],"dexamethasone":[132,164],"(D-Rd)":[133],"demonstrated":[134],"significant":[135,168],"PFS":[136,399,637],"(hazard":[137],"ratio":[138],"[HR]=0.53,":[139],"P<0.0001)":[140],"OS":[142,169,479,514,528,585,591,624,641,690],"(HR=0.68,":[143],"P=0.0013)":[144],"benefit":[145,170,592],"vs":[146,171,265],"Rd.":[147,172],"subgroup":[150],"\u226565":[153],"years":[154,533,556,687],"old":[155],"SWOG":[158],"S0777":[159],"study,":[160],"bortezomib,":[161],"(VRd)":[165],"had":[166,508],"absence":[175],"head-to-head":[177],"studies":[178],"comparing":[179],"different":[180,191,253,604,626],"sequences,":[182,606],"clinical":[183,222,239,254,259,277,285,325],"can":[186],"used":[188,493],"explore":[190,257],"scenarios.":[192],"Published":[193],"models":[194,210],"suggest":[195],"delaying":[197,536],"DARA":[198,263],"until":[199,268,539,645],"LOT":[201,234,647],"viable":[204],"strategy.":[206],"Limitations":[207],"these":[209],"include":[211],"basing":[212],"conclusions":[213],"on":[214,237,303,312,379,417,477,623,665,740,755,773,880,894,925,939,965,981,994],"sequences":[216,279,321,611],"other":[217],"than":[218,502,561],"those":[219,249,361],"recommended":[220],"guidelines,":[223],"accounting":[225],"for":[226,241,409,612],"from":[230,389,482,725],"1L":[231,301,329,345,370,525,639],"subsequent":[233,307,316],"relying":[236],"inappropriate":[238],"inputs":[240],"second-line":[242],"(2L)":[243],"beyond.":[246],"While":[247],"addressing":[248],"limitations,":[250],"we":[251,607],"examined":[252,274],"scenarios":[255],"value":[260],"using":[262,280,713],"first":[264],"saving":[266],"it":[267,425],"LOT.":[271],"Methods:":[272],"We":[273,511],"3":[275,297],"potential":[276],"lifetime":[282],"three-health":[283],"state":[284,372,467],"simulation":[286],"estimate":[288,445],"outcomes":[290,602],"TIE":[294,677],"NDMM.":[295],"health":[298,371,466],"states":[299],"were:":[300],"(time":[302,311],"+":[305,314],"any":[306,315],"tx-free":[308],"interval),":[309],"2L":[310,313,339,351,465,498,540,696,704],"LOT),":[317],"death.":[319],"Tx":[320],"were":[322,355,395,429,452,492],"reflective":[323],"guidelines:":[326],"D-Rd":[327,374,523,560,681],"followed":[330,346],"by":[331,347,397,529,662],"pomalidomide":[332],"(POM)-":[333],"or":[334,342,384,472,531,543,564,746,761,779,886,900,931,945,971,987,1000],"carfilzomib":[335],"(CAR)-based":[336],"regimens":[337,349,474,538],"VRd":[341,394,542,563],"Rd":[343,376,565],"DARA-based":[348,469,537],"(Figure).":[352],"Pt":[353],"characteristics":[354],"assumed":[356,453],"similar":[359,421],"MAIA.":[365],"Time":[366,461],"spent":[367,462],"was":[377,415,475,557,586],"based":[378,416,476],"time":[380],"next":[382],"death":[385],"(TTNT)":[386],"curves":[387,392,480],"derived":[388,396,481],"MAIA;":[390],"TTNT":[391],"applying":[398],"HRs":[400],"estimated":[401],"PEGASUS":[404],"study.":[405],"rate":[408],"base":[411],"case":[412],"analysis":[413,440],"(58.8%)":[414],"data.":[419],"Although":[420],"published":[423,497,663],"studies,":[424],"includes":[426],"who":[428],"lost":[430],"follow-up":[432],"overestimate.":[437],"A":[438],"sensitivity":[439],"evaluated":[441,512],"more":[443],"conservative":[444],"(27.2%)":[446],"excluding":[447],"censored":[448],"pts.":[449],"Attrition":[450],"same":[457],"across":[458],"arms.":[460],"POM-":[471],"CAR-based":[473],"RW":[478,490],"nationwide":[484],"EHR-derived":[485],"deidentified":[486],"Flatiron":[487],"Health":[488],"database.":[489],"as":[494,566,660],"trials":[499],"younger":[501],"prior":[509],"ASCT.":[510],"median":[513,527,577,584],"5-":[516],"10-year":[518],"rates.":[520],"Results:":[521],"Using":[522],"2.5":[530],"3.5":[532,686],"compared":[534],"after":[541],"Rd,":[544],"respectively":[545],"(Table).":[546,569],"probability":[548,721],"being":[550],"alive":[551],"at":[552],"5":[553],"10":[555],"higher":[558],"initial":[567],"Changes":[570],"impacted":[574],"expected":[576],"OS,":[578],"but":[579],"absolute":[581],"difference":[582],"maintained,":[587],"incremental":[590],"consistently":[593],">2":[594],"years.":[595],"Conclusions:":[596],"Unlike":[597],"previous":[598],"attempts":[599],"examine":[601],"incorporated":[608],"clinically":[609],"representative":[610],"NDMM,":[615,678],"included":[616],"rates,":[618],"explored":[620],"their":[621],"impact":[622],"sequences.":[628],"Our":[629,670],"approach":[630],"shows":[631],"drives":[640],"outcomes.":[642],"Saving":[643],"agents":[644,705,716],"does":[648],"take":[650],"into":[651],"account":[652],"do":[656],"reach":[658],"2L,":[659],"evidenced":[661],"MM.":[669],"findings":[671],"show":[672],"starting":[679],"provide":[683],"additional":[689],"gain":[691,699],"currently":[694,706,727],"available":[695],"tx.":[697],"This":[698],"could":[700],"increase":[701,719],"new":[703],"development,":[708],"reinforcing":[709],"importance":[711],"best":[715],"first,":[717],"benefitting":[724],"development.":[729],"Figure":[730,732],"1":[731],"1.":[733],"Disclosures":[734],"Fonseca:":[735],"Caris":[736],"Life":[737],"Sciences:":[738],"Membership":[739,754,772,879,893,924,938,964,980,993],"entity's":[742,757,775,882,896,927,941,967,983,996],"Board":[743,758,776,883,897,928,942,968,984,997],"Directors":[745,760,778,885,899,930,944,970,986,999],"advisory":[747,762,780,887,901,932,946,972,988,1001],"committees;":[748,763,781],"Scientific":[749],"Advisory":[750],"Board:":[751],"Adaptive":[752],"Biotechnologies:":[753],"Kite:":[764],"Consultancy;":[765,767,769,783,794,802,804,806,808,810,812,814,816,818,876,951,954],"Janssen:":[766,835,845,855,865,936],"GSK:":[768],"OncoTracker:":[770],"Consultancy,":[771,878,892,909,913,916,923,937,956,963],"Aduro:":[782],"Patent:":[784],"Prognosticaton":[785],"via":[788],"FISH:":[789],"Patents":[790],"&":[791,830],"Royalties;":[792],"AbbVie:":[793],"Mayo":[795],"Clinic":[796],"Arizona:":[798],"Current":[799,825,832,836,838,846,848,856,858,866,868],"Employment;":[800],"BMS:":[801,955],"Celgene:":[803,979],"Amgen:":[805,908],"Bayer:":[807],"Novartis:":[809,905],"Pharmacyclics:":[811],"Sanofi:":[813,1005],"Juno:":[815],"Takeda:":[817,922],"Merck:":[819,976],"Consultancy.":[820],"Hashim:":[821],"Johnson":[822],"Johnson:":[824],"Employment.":[826,833],"Nair:":[827],"Janssen":[828],"Research":[829,889,903,906,910,917,920,934,948,957,960,974,977,990,1003,1006],"Development:":[831],"He:":[834],"Employment,":[837,847,857,867],"equity":[839,849,859,869],"holder":[840,850,860,870],"publicly-traded":[842,852,862,872],"company.":[843,853,863,873],"Ammann:":[844],"Lam:":[854],"Wildgust:":[864],"Kumar:":[874],"Beigene:":[875],"Abbvie:":[877],"committees,":[888,902,933,947,973,989,1002],"Funding;":[890,904,907,911,918,921,935,949,958,961,975,978,991,1004],"KITE:":[891],"Antengene:":[912],"Honoraria;":[914],"Roche-Genentech:":[915],"Tenebio:":[919],"Oncopeptides:":[950],"Bluebird":[952],"Bio:":[953],"Carsgen:":[959],"Astra-Zeneca:":[962],"Adaptive:":[992],"Funding.":[1007]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2025-10-10T00:00:00"}